The company reported Q3 revenue of $76.874 million, nearly all of it ($76.622 million) coming from continuing operations, up 11% sequentially from Q2 and 52% year-over-year thanks to a 77% year-over-year growth in revenue from exome and genome tests
For patients who had a bariatric procedure performed in the past that was not ultimately successful, Cigna may cover a revision bariatric surgery
Understanding your genetic profile can support a more informed conversation with your provider about whether you might benefit from preventive strategies, dose-level adjustments, or closer monitoring during tirzepatide initiation
That means fueling intelligently
This planning helps ensure you dont accidentally conceive too soon after stopping
See our Fit & Toned IV, Myers Cocktail IV, and Fitness Tri-Amino Acid Boost.